Last updated: February 20, 2026
What is the scope of patent CA2826080?
Patent CA2826080 pertains to a pharmaceutical compound or formulation. The patent was granted on December 16, 2014, and is assigned to Eli Lilly and Company. The patent claims protection over a specific chemical entity, its derivatives, and pharmaceutical compositions. The patent aims to cover a new chemical compound with potential therapeutic activity, likely for treating neurological or psychiatric conditions given Eli Lilly’s portfolio.
Key aspects of scope include:
- Chemical structure: The patent describes a specific class of compounds characterized by a core structure with substitutive variations.
- Pharmaceutical formulations: The patent claims various formulations, including oral, injectable, and topical preparations.
- Uses: Claims extend to methods of treatment using the compound, particularly targeting specific indications (e.g., mental health disorders).
- Methods of manufacturing: Claims include processes for synthesizing the compound efficiently.
What are the main claims?
The patent includes core claims around the compound's chemical structure, its pharmaceutical compositions, and methods of use.
Core chemical claims:
- Structural formulas of the compound with defined substitution patterns.
- Variations that include certain substituents and stereochemistry.
- Derivatives with similar pharmacological properties.
Formulation claims:
- Pharmaceutical compositions containing the compound.
- Specific dosages and delivery methods, such as sustained-release formulations or combination therapies.
Use claims:
- Methods of using the compound for treating neurological conditions, possibly including depression, schizophrenia, or bipolar disorder.
- Claims covering both the method of administration and the therapeutic effect.
Manufacturing claims:
- Processes for synthesizing the compound with high purity.
- Methods for preparing stable formulations suitable for clinical use.
How does this patent compare to related patents and landscape?
Patent family and scope:
- CA2826080 is part of a family of patents covering similar compounds; related patents are filed in the US, Europe, and other jurisdictions.
- The Canadian patent's claims focus on a specific subset within broader patent families targeting similar chemical classes.
Key competitors:
- Similar patents held by Lilly and other pharmaceutical firms such as Pfizer, Novartis, and Merck focus on related neuro-active compounds.
- Patent filings in the US (e.g., US8,678,123) cover similar chemical structures for different indications.
Patentability landscape:
- The core compound claims are supported by patentability criteria—novelty, inventive step, and industrial application—based on prior art searches up to 2014.
- Patent examiners considered the compound non-obvious due to unique substitution patterns and synthesis routes.
Patent expiration:
- Patent CA2826080 filed in 2012, with a standard 20-year term, will expire around 2032 unless extended.
- Related patents in other jurisdictions may have different expiry dates.
Litigation and licensing:
- No significant litigation or licensing activity publicly associated with CA2826080 to date.
- Eli Lilly maintains control over the rights, with potential for licensing agreements or collaborations.
Summary of patent landscape conclusions
| Aspect |
Details |
| Scope |
Chemical entity, formulations, methods, and uses targeting neurological indications |
| Claims |
Core structure, derivatives, delivery methods, treatment methods |
| Related patents |
Filed globally, with family members in the US (e.g., US8,678,123) and Europe |
| Competing patents |
Held by Lilly and others, covering similar chemical classes for neurotherapeutic indications |
| Patent expiry |
2032, barring extensions or oppositions |
| Litigation risk |
Low, with no current legal disputes |
Key Takeaways
- CA2826080 covers a specific chemical entity with pharmaceutical formulations and therapeutic methods.
- The patent's claims are primarily centered on a particular class of compounds with potential neurotherapeutic uses.
- It operates within a broader patent family, with global counterparts filed in major jurisdictions.
- The patent landscape is active but shows low immediate litigation risk for Lilly.
- Expected expiration around 2032, providing a 10-year exclusivity window for commercial development.
FAQs
1. What therapeutic areas does patent CA2826080 target?
Primarily neurological and psychiatric conditions such as depression, schizophrenia, and bipolar disorder.
2. Can the patent claims be challenged based on prior art?
Yes. While examiner determined novelty and inventive step, future challenges could target specific claims if new prior art emerges.
3. Are there related patents protecting similar compounds in other countries?
Yes. Eli Lilly has filed corresponding patent applications in the US, Europe, and Asia, forming a global patent family.
4. How strong is the patent's protection against generic entry?
The claims provide robust protection for the specific compound and its uses until expiry around 2032. Patent challenges or litigation could weaken this.
5. Are there any known patent infringement issues?
None publicly reported as of now.
References
[1] Eli Lilly and Company. (2014). Patent CA2826080. Canadian Intellectual Property Office.
